The REWIND, PIONEER 4 and PIONEER 6 trials of GLP1R agonists show the cardiovascular benefits of dulaglutide in patients with diabetes and no previous cardiovascular events and that oral semaglutide is safe and noninferior to subcutaneous injections of liraglutide.
CITATION STYLE
Lim, G. B. (2019, August 1). GLP1R agonists: primary cardiovascular prevention and oral administration. Nature Reviews Cardiology. Nature Publishing Group. https://doi.org/10.1038/s41569-019-0232-z
Mendeley helps you to discover research relevant for your work.